Risk of Hospitalisation and Death Due to Bone Fractures After Breast Cancer: a Registry-based Cohort Study

Overview

Journal Br J Cancer

Specialty Oncology

Date 2016 Oct 5

PMID 27701383

Citations 12

Authors

Edoardo Colzani

Mark Clements

Anna L V Johansson

Annelie Liljegren

Wei He

Judith Brand

Jan Adolfsson

Tommy Fornander

Per Hall

Kamila Czene

Affiliations

Soon will be listed here.

Abstract

Background: Bone fractures may have an impact on prognosis of breast cancer. The long-term risks of bone fracture in breast cancer patients have not been thoroughly studied.

Methods: Poisson regression was used to investigate the incidence of hospitalisation due to bone fracture comparing women with and without breast cancer based on Swedish National registers. Cox regression was used to investigate the risk of being hospitalised with bone fracture, and subsequent risk of death, in a regional cohort of breast cancer patients.

Results: For breast cancer patients, the 5-year risk of bone fracture hospitalisation was 4.8% and the 30-day risk of death following a bone fracture hospitalisation was 2.0%. Compared with the general population, breast cancer patients had incidence rate ratios of 1.25 (95% CI: 1.23-1.28) and 1.18 (95% CI: 1.14-1.22) for hospitalisation due to any bone fracture and hip fracture, respectively. These ratios remained significantly increased for 10 years. Comorbidities (Charlson Comorbidity Index ⩾1) were associated with the risk of being hospitalised with bone fracture. Women taking aromatase inhibitors were at an increased risk as compared with women taking tamoxifen (HR=1.48; 95% CI: 0.98-2.22). Breast cancer patients hospitalised for a bone fracture showed a higher risk of death (HR=1.83; 95% CI: 1.50-2.22) compared with those without bone fracture.

Conclusions: Women with a previous breast cancer diagnosis are at an increased risk of hospitalisation due to a bone fracture, particularly if they have other comorbidities.

Citing Articles

Physical therapist management and coordination of care to prevent pathological hip fracture from metastatic disease: a case report.

Manzino A, Wilson C Front Rehabil Sci. 2024; 5:1384782.

PMID: 39363992 PMC: 11446967. DOI: 10.3389/fresc.2024.1384782.

Lau G, Ibrahim M, OBrien S, Loiselle C Can Oncol Nurs J. 2024; 32(3):408-415.

PMID: 38919672 PMC: 11195581. DOI: 10.5737/23688076323408.

Bone fragility related to breast cancer treatment: The pivotal role of nurses in bone health program development, implementation, and testing.

Lau G, Ibrahim M, OBrien S, Loiselle C Can Oncol Nurs J. 2024; 32(3):401-407.

PMID: 38919669 PMC: 11195586. DOI: 10.5737/23688076323401.

Gynecologic Care of Black Breast Cancer Survivors.

Pleasant V Curr Breast Cancer Rep. 2024; 16(1):84-97.

PMID: 38725438 PMC: 11081127. DOI: 10.1007/s12609-024-00527-4.

Initiation of Antiresorptive Drug Treatment during Endocrine Therapy for Breast Cancer-A Retrospective Cohort Study of 161,492 Patients in Germany.

Gremke N, Griewing S, Kadys A, Kostev K, Wagner U, Kalder M Cancers (Basel). 2023; 15(6).

PMID: 36980733 PMC: 10047063. DOI: 10.3390/cancers15061847.

References

Edwards B, Raisch D, Shankaran V, McKoy J, Gradishar W, Bunta A . Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res. 2011; 17(3):560-8. PMC: 3058419. DOI: 10.1158/1078-0432.CCR-10-1595. View

Sogaard M, Thomsen R, Bossen K, Sorensen H, Norgaard M . The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013; 5(Suppl 1):3-29. PMC: 3820483. DOI: 10.2147/CLEP.S47150. View

Benoy I, Elst H, Philips M, Wuyts H, van Dam P, Scharpe S . Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer. 2006; 94(5):672-80. PMC: 2361203. DOI: 10.1038/sj.bjc.6602985. View

Thorstenson A, Bratt O, Akre O, Hellborg H, Holmberg L, Lambe M . Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden. Eur J Cancer. 2012; 48(11):1672-81. DOI: 10.1016/j.ejca.2012.01.035. View

Van Hemelrijck M, Garmo H, Michaelsson K, Thorstenson A, Akre O, Stattin P . Mortality following hip fracture in men with prostate cancer. PLoS One. 2013; 8(9):e74492. PMC: 3785484. DOI: 10.1371/journal.pone.0074492. View

Arnold P . Radiation-induced fracture. J Neurosurg Spine. 2013; 18(5):428-9. DOI: 10.3171/2013.1.SPINE121161. View

Nakase J, Toribatake Y, Mouri Y, Seki H, Kitaoka K, Tomita K . Heparin versus danaproid for prevention of venous thromboembolism after hip surgery. J Orthop Surg (Hong Kong). 2009; 17(1):6-9. DOI: 10.1177/230949900901700102. View

Cooke A, Metge C, Lix L, Prior H, Leslie W . Tamoxifen use and osteoporotic fracture risk: a population-based analysis. J Clin Oncol. 2008; 26(32):5227-32. DOI: 10.1200/JCO.2007.15.7123. View

Rutqvist L, Johansson H . Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol. 2007; 46(2):133-45. DOI: 10.1080/02841860601034834. View

10.

Coleman R, Body J, Aapro M, Hadji P, Herrstedt J . Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014; 25 Suppl 3:iii124-37. DOI: 10.1093/annonc/mdu103. View

11.

Fisher B, Costantino J, Redmond C, POISSON R, Bowman D, Couture J . A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989; 320(8):479-84. DOI: 10.1056/NEJM198902233200802. View

12.

Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P . Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2012; 24(2):398-405. DOI: 10.1093/annonc/mds277. View

13.

He M, Fan W, Zhang X . Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis. J Hematol Oncol. 2013; 6(1):80. PMC: 3874690. DOI: 10.1186/1756-8722-6-80. View

14.

Chen Z, Maricic M, Aragaki A, Mouton C, Arendell L, Lopez A . Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women's Health Initiative. Osteoporos Int. 2008; 20(4):527-36. PMC: 2895418. DOI: 10.1007/s00198-008-0721-0. View

15.

. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet. 1987; 2(8552):171-5. View

16.

Anand S, Buch K . Post-discharge symptomatic thromboembolic events in hip fracture patients. Ann R Coll Surg Engl. 2007; 89(5):517-20. PMC: 2048602. DOI: 10.1308/003588407X202065. View

17.

Van Poznak C, Hannon R, Mackey J, Campone M, Apffelstaedt J, Clack G . Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol. 2010; 28(6):967-75. DOI: 10.1200/JCO.2009.24.5902. View

18.

Bliuc D, Nguyen N, Milch V, Nguyen T, Eisman J, Center J . Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009; 301(5):513-21. DOI: 10.1001/jama.2009.50. View

19.

Amir E, Seruga B, Niraula S, Carlsson L, Ocana A . Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011; 103(17):1299-309. DOI: 10.1093/jnci/djr242. View

20.

Semesiuk N, Zhylchuk A, Bezdenezhnykh N, Lykhova A, Vorontsova A, Zhylchuk V . Disseminated tumor cells and enhanced level of some cytokines in bone marrow and peripheral blood of breast cancer patients as predictive factors of tumor progression. Exp Oncol. 2014; 35(4):295-302. View